| Dr Donald Chapman, DO | |
|
500 Medical Center Blvd Ste 135, Lawrenceville, GA 30046 | |
| (678) 312-2400 | |
| Not Available |
| Full Name | Dr Donald Chapman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 500 Medical Center Blvd Ste 135, Lawrenceville, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154731388 | NPI | - | NPPES |
| 5101021173 | Other | MI | OSTEOPATHIC MEDICINE AND SURGERY PHYSICIAN LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5101021173 (Michigan) | Secondary |
| 207P00000X | Emergency Medicine | 82335 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northside Hospital Gwinnett | Lawrenceville, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gwinnett Emergency Specialists Observation Services Llc | 7618140955 | 28 |
| Gwinnett Emergency Specialists Pc | 0840373619 | 41 |
News Archive
Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defense-cells called microglia-unique.
More than half of early-career scientists who received their first research project grants from the National Institute of Allergy and Infectious Diseases are successful in obtaining subsequent funding from the National Institutes of Health, according to a study published September 12 in the open-access journal PLOS ONE by Patricia Haggerty and Matthew Fenton of NIAID, an NIH institute.
Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.
Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.
› Verified 7 days ago
| Entity Name | Northside Emergency Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285686303 PECOS PAC ID: 9335135144 Enrollment ID: O20040426000165 |
News Archive
Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defense-cells called microglia-unique.
More than half of early-career scientists who received their first research project grants from the National Institute of Allergy and Infectious Diseases are successful in obtaining subsequent funding from the National Institutes of Health, according to a study published September 12 in the open-access journal PLOS ONE by Patricia Haggerty and Matthew Fenton of NIAID, an NIH institute.
Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.
Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.
› Verified 7 days ago
| Entity Name | Gwinnett Emergency Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437346467 PECOS PAC ID: 0840373619 Enrollment ID: O20080218000080 |
News Archive
Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defense-cells called microglia-unique.
More than half of early-career scientists who received their first research project grants from the National Institute of Allergy and Infectious Diseases are successful in obtaining subsequent funding from the National Institutes of Health, according to a study published September 12 in the open-access journal PLOS ONE by Patricia Haggerty and Matthew Fenton of NIAID, an NIH institute.
Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.
Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.
› Verified 7 days ago
| Entity Name | Gwinnett Emergency Specialists Observation Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720373129 PECOS PAC ID: 7618140955 Enrollment ID: O20111101000364 |
News Archive
Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defense-cells called microglia-unique.
More than half of early-career scientists who received their first research project grants from the National Institute of Allergy and Infectious Diseases are successful in obtaining subsequent funding from the National Institutes of Health, according to a study published September 12 in the open-access journal PLOS ONE by Patricia Haggerty and Matthew Fenton of NIAID, an NIH institute.
Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.
Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald Chapman, DO 500 Medical Center Blouvard Suite 135, Lawrenceville, GA 30046 Ph: () - | Dr Donald Chapman, DO 500 Medical Center Blvd Ste 135, Lawrenceville, GA 30046 Ph: (678) 312-2400 |
News Archive
Scientists have, for the first time, characterized the molecular markers that make the brain's front lines of immune defense-cells called microglia-unique.
More than half of early-career scientists who received their first research project grants from the National Institute of Allergy and Infectious Diseases are successful in obtaining subsequent funding from the National Institutes of Health, according to a study published September 12 in the open-access journal PLOS ONE by Patricia Haggerty and Matthew Fenton of NIAID, an NIH institute.
Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.
Ever since the beginning of the international spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease, researchers have been trying to identify the risk factors that increase the chances of infection. Now, a new study published on the preprint server medRxiv in May 2020 discusses various potential factors and reports the observed associations.
› Verified 7 days ago
Amanarh Albert Kisseih, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30045 Phone: 678-442-3317 Fax: 678-442-4416 | |
Dr. Anna Carolyn Nay, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 Medical Center Blvd Ste 135, Lawrenceville, GA 30046 Phone: 678-312-3317 | |
Donald Alfred Ruf, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30045 Phone: 678-442-3317 Fax: 678-442-4416 | |
Roy Gilbreath, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1185 Rivershyre Pkwy, Lawrenceville, GA 30043 Phone: 678-591-7640 | |
Tiffany Mckinnie, M.D Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30046 Phone: 678-312-4416 | |
Danielle Hines, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30046 Phone: 678-312-3317 | |
Dr. James Lofton Smith Jr., M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Medical Center Blvd, Lawrenceville, GA 30045 Phone: 678-442-3317 Fax: 678-442-4416 |